Login to Your Account



ECCMID Roundup


Tuesday, April 3, 2012
• Optimer Pharmaceuticals Inc., of San Diego, presented results from a post-hoc subgroup analysis of the company's two large Phase III trials, which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained response and lower recurrence when treated with Dificid (fidaxomicin) tablets compared to oral vancomycin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription